MetSCORE: a Molecular Metric to Evaluate the Risk of Metabolic Syndrome Based on Serum NMR Metabolomics

Background: Metabolic syndrome (MetS) is a cluster of medical conditions and risk factors correlating with insulin resistance that increase the risk of developing cardiometabolic health problems. The specific criteria for diagnosing MetS vary among different medical organizations but are typically based on the evaluation of abdominal obesity, high blood pressure, hyperglycemia, and dyslipidemia. A unique, quantitative and independent estimation of the risk of MetS based only on quantitative biomarkers is highly desirable for the comparison between patients and to study the individual progression of the disease in a quantitative manner.

Methods: We used NMR-based metabolomics on a large cohort of donors (n = 21,323; 37.5% female) to investigate the diagnostic value of serum or serum combined with urine to estimate the MetS risk. Specifically, we have determined 41 circulating metabolites and 112 lipoprotein classes and subclasses in serum samples and this information has been integrated with metabolic profiles extracted from urine samples.

Results: We have developed MetSCORE, a metabolic model of MetS that combines serum lipoprotein and metabolite information. MetSCORE discriminate patients with MetS (independently identified using the WHO criterium) from general population, with an AUROC of 0.94 (95% CI 0.920-0.952, p < 0.001). MetSCORE is also able to discriminate the intermediate phenotypes, identifying the early risk of MetS in a quantitative way and ranking individuals according to their risk of undergoing MetS (for general population) or according to the severity of the syndrome (for MetS patients).

Conclusions: We believe that MetSCORE may be an insightful tool for early intervention and lifestyle modifications, potentially preventing the aggravation of metabolic syndrome.

References

Bizkarguenaga M, Gil-Redondo R, Bruzzone C, Bernardo-Seisdedos G, Lain A, Gonzalez-Valle B . Prospective Metabolomic Studies in Precision Medicine: The AKRIBEA Project. Handb Exp Pharmacol. 2022; 277:275-297. DOI: 10.1007/164_2022_610. View

Pauck Bernhardsen G, Thomas O, Mantyselka P, Niskanen L, Vanhala M, Koponen H . Metabolites and depressive symptoms: Network- and longitudinal analyses from the Finnish Depression and Metabolic Syndrome in Adults (FDMSA) Study. J Affect Disord. 2023; 347:199-209. DOI: 10.1016/j.jad.2023.11.070. View

Dona A, Jimenez B, Schafer H, Humpfer E, Spraul M, Lewis M . Precision high-throughput proton NMR spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping. Anal Chem. 2014; 86(19):9887-94. DOI: 10.1021/ac5025039. View

Haffner S . Relationship of metabolic risk factors and development of cardiovascular disease and diabetes. Obesity (Silver Spring). 2006; 14 Suppl 3:121S-127S. DOI: 10.1038/oby.2006.291. View

Monnerie S, Comte B, Ziegler D, Morais J, Pujos-Guillot E, Gaudreau P . Metabolomic and Lipidomic Signatures of Metabolic Syndrome and its Physiological Components in Adults: A Systematic Review. Sci Rep. 2020; 10(1):669. PMC: 6971076. DOI: 10.1038/s41598-019-56909-7. View

Lent-Schochet D, McLaughlin M, Ramakrishnan N, Jialal I . Exploratory metabolomics of metabolic syndrome: A status report. World J Diabetes. 2019; 10(1):23-36. PMC: 6347655. DOI: 10.4239/wjd.v10.i1.23. View

Maher A, Lindon J, Nicholson J . ¹H NMR-based metabonomics for investigating diabetes. Future Med Chem. 2011; 1(4):737-47. DOI: 10.4155/fmc.09.54. View

Bruzzone C, Gil-Redondo R, Seco M, Barragan R, de la Cruz L, Cannet C . A molecular signature for the metabolic syndrome by urine metabolomics. Cardiovasc Diabetol. 2021; 20(1):155. PMC: 8320177. DOI: 10.1186/s12933-021-01349-9. View

Otvos J, Jeyarajah E, Bennett D, Krauss R . Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem. 1992; 38(9):1632-8. View

10.

Lu B, Qian J, Li J . The metabolic syndrome and its components as prognostic factors in colorectal cancer: A meta-analysis and systematic review. J Gastroenterol Hepatol. 2022; 38(2):187-196. PMC: 10100176. DOI: 10.1111/jgh.16042. View

11.

Sandsdal R, Juhl C, Jensen S, Lundgren J, Janus C, Blond M . Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc Diabetol. 2023; 22(1):41. PMC: 9960425. DOI: 10.1186/s12933-023-01765-z. View

12.

Jeyarajah E, Cromwell W, Otvos J . Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006; 26(4):847-70. DOI: 10.1016/j.cll.2006.07.006. View

13.

Mocciaro G, DAmore S, Jenkins B, Kay R, Murgia A, Herrera-Marcos L . Lipidomic Approaches to Study HDL Metabolism in Patients with Central Obesity Diagnosed with Metabolic Syndrome. Int J Mol Sci. 2022; 23(12). PMC: 9223701. DOI: 10.3390/ijms23126786. View

14.

Kassi E, Pervanidou P, Kaltsas G, Chrousos G . Metabolic syndrome: definitions and controversies. BMC Med. 2011; 9:48. PMC: 3115896. DOI: 10.1186/1741-7015-9-48. View

15.

Kamel M, Smith B, Wahi G, Carsley S, Birken C, Anderson L . Continuous cardiometabolic risk score definitions in early childhood: a scoping review. Obes Rev. 2018; 19(12):1688-1699. DOI: 10.1111/obr.12748. View

16.

Strazzullo P, Barbato A, Siani A, Cappuccio F, Versiero M, Schiattarella P . Diagnostic criteria for metabolic syndrome: a comparative analysis in an unselected sample of adult male population. Metabolism. 2008; 57(3):355-61. DOI: 10.1016/j.metabol.2007.10.010. View

17.

Li X, Liang Q, Zhong J, Gan L, Zuo L . The Effect of Metabolic Syndrome and Its Individual Components on Renal Function: A Meta-Analysis. J Clin Med. 2023; 12(4). PMC: 9962508. DOI: 10.3390/jcm12041614. View

18.

Ambroselli D, Masciulli F, Romano E, Catanzaro G, Besharat Z, Massari M . New Advances in Metabolic Syndrome, from Prevention to Treatment: The Role of Diet and Food. Nutrients. 2023; 15(3). PMC: 9921449. DOI: 10.3390/nu15030640. View

19.

Shim K, Gulhar R, Jialal I . Exploratory metabolomics of nascent metabolic syndrome. J Diabetes Complications. 2019; 33(3):212-216. DOI: 10.1016/j.jdiacomp.2018.12.002. View

20.

Ridker P, Buring J, Cook N, Rifai N . C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003; 107(3):391-7. DOI: 10.1161/01.cir.0000055014.62083.05. View